Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL619526 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2LMNAALDH1A1POLBCYP1A2 | |
| SCHEMBL3985690 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2LMNAALDH1A1POLBCYP1A2 | |
| SCHEMBL5473681 | 0.86 | SMN1; SMN2 (0.64) | SMN1; SMN2LMNAALDH1A1POLBCYP1A2 | |
| SCHEMBL255679 | 0.84 | CYP1A2 (0.71) | SMN1; SMN2LMNAALDH1A1POLBCYP1A2 | |
| SCHEMBL255663 | 0.84 | CYP1A2 (0.71) | SMN1; SMN2LMNAALDH1A1POLBCYP1A2 | |
| SCHEMBL255664 | 0.84 | CYP1A2 (0.71) | SMN1; SMN2LMNAALDH1A1POLBCYP1A2 | |
| SCHEMBL20791688 | 0.83 | L3MBTL1 (0.53) | SMN1; SMN2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL20791689 | 0.83 | L3MBTL1 (0.53) | SMN1; SMN2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL8309864 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAALDH1A1POLBCYP1A2 | |
| SCHEMBL14521538 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAALDH1A1POLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11890288-B2 | Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-02-06 | — | — | US | disclosed |
| US-20230364105-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-16 | — | — | US | disclosed |
| US-20230146717-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| WO-2023025225-A1 | CYCLIN K DEGRADATION AGENT | 杭州阿诺生物医药科技有限公司 | 2023-03-02 | — | — | WO | disclosed |
| EP-4105220-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2022-12-21 | — | — | EP | disclosed |
| EP-2460787-A1 | Amide compounds and their use as PGE2 antagonists. | Astellas Pharma Inc. (JP) | 2012-06-06 | — | — | EP | disclosed |
| EP-2222631-B1 | SUBSTITUTED PHENYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER (US) | 2011-08-17 | — | — | EP | disclosed |
| US-7960365-B2 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| US-20100234435-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | BHATTACHARYA SAMIT K | 2010-09-16 | — | — | US | disclosed |
| US-7790754-B2 | Alpha-hydroxy amides as bradykinin antagonists or inverse agonists | MERCK SHARP & DOHME CORP. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2007-06-28 | — | — | US | disclosed |
| CN-1898198-A | Alpha-hydroxy amides as bradykinin antagonists or inverse agonists | MERCK & CO INC (US) | 2007-01-17 | — | — | CN | disclosed |
| US-7091380-B2 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1476419-B1 | N-BIPHENYLMETHYL AMINOCYCLOALKANECARBOXAMIDE DERIVATIVES | MERCK & CO INC (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1501787-B1 | N-BIPHENYLMETHYL AMINOCYCLOALKANECARBOXAMIDE DERIVATIVES WITH A SUBSTIITUENT ON THE METHYL USEFUL AS BRADYKININ ANTAGONISTS | MERCK & CO INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6919343-B2 | N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives | MERCK & CO., INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20050085667-A1 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives | MERCK SHARP & DOHME LLC | 2005-04-21 | — | — | US | disclosed |
| US-20050084463-A1 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substiituent on the methyl useful as bradykinin antagonists | WOOD MICHAEL R (US) | 2005-04-21 | — | — | US | disclosed |
| US-20030220375-A1 | N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives | MERCK SHARP & DOHME LLC | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | NR3C1, NR3C2, MC2R | SMN1; SMN2 2173/4885LMNA 3879/4885ALDH1A1 1050/4885 |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | SMN1; SMN2 2291/4885LMNA 515/4885ALDH1A1 1502/4885 |
| US-20100234435-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | CCNI, CCNA1, PCNA | SMN1; SMN2 3966/4885LMNA 1693/4885ALDH1A1 509/4885 |
| US-11890288-B2 | Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof | BRD4, BRD1, BRD2 | SMN1; SMN2 2513/4885LMNA 3531/4885ALDH1A1 4137/4885 |
| US-20230146717-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | BRD4, BRD1, BRD2 | SMN1; SMN2 2513/4885LMNA 3531/4885ALDH1A1 4137/4885 |
| US-20030220375-A1 | N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives | BDKRB1, BDKRB2, CNR2 | SMN1; SMN2 3104/4885LMNA 1121/4885ALDH1A1 3175/4885 |
| US-20230364105-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | BRD4, BRD1, BRD2 | SMN1; SMN2 2513/4885LMNA 3531/4885ALDH1A1 4137/4885 |
| US-20050084463-A1 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substiituent on the methyl useful as bradykinin antagonists | BDKRB1, BDKRB2, CNR2 | SMN1; SMN2 3608/4885LMNA 1306/4885ALDH1A1 3872/4885 |
| US-20050085667-A1 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives | BDKRB1, BDKRB2, LTB4R2 | SMN1; SMN2 3577/4885LMNA 1131/4885ALDH1A1 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.